Genentech Files Complaint Over Amgen’s Development of Avastin Biosimilar
Genentech Files Complaint Over Amgen’s Development of Avastin Biosimilar Roche’s Genentech filed a complaint in Delaware District Court last week charging that Amgen, which is developing a biosimilar version of Genentech’s blockbuster cancer treatment Avastin (bevacizumab), has obstructed its ability to determine whether the manufacture and/or sale of Amgen’s biosimilar would infringe Genentech’s patents.
Celltrion’s Rituximab Biosimilar Truxima Approved in Europe
Celltrion’s Rituximab Biosimilar Truxima Approved in Europe The European Commission cleared Celltrion Healthcare’s rituximab biosimilar Truxima™ for all approved indications of its reference drug, Roche’s blockbuster MabThera/Rituxan, including non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis, and microscopic polyangiitis. Truxima is the first biosimilar approved for a cancer indication in Europe. “We are excited to
Biocon, Mylan allowed to sell 3 cancer biosimilars
Biocon, Mylan allowed to sell 3 cancer biosimilars Mumbai, March 3: The legal battle involving drugmaker Roche’s breast cancer drug Trastuzumab took a significant turn on Friday with the Delhi High Court allowing drugmakers Biocon and Mylan to sell their version of the biosimilar drug for three treatment indications. Biocon and Mylan will now be able to sell their version
UK court delivers high-stakes decision on world’s best-selling drug
UK court delivers high-stakes decision on world’s best-selling drug South Korea’s Samsung Bioepis has won a high-stakes court case on Friday against U.S. drug firm AbbVie for a biosimilar of the world’s best-selling drug. Samsung is hoping to sell a version of arthritis treatment Humira in European markets as early as next year pending approval by the European Medicines Agency
Biosimilars: The Pipeline Seams Seem To Be Bursting
Hundreds of products are at some stage of development, but only a handful may get on the market in the next few years. The biosimilar segment of the pharmaceutical industry is on fire. Some 700 biosimilars are at some stage of development, according to Biosimilarpipeline, and the website reports that more than 660 companies are involved in some way in
